RESEARCH ARTICLE

A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty

Nicolas Martelli1,2*, Capucine Devaux1*, Hélène van den Brink2, Judith Pineau1, Patrice Prognon1, Isabelle Borget2,3

1 Pharmacy Department, Georges Pompidou European Hospital, AP-HP, 20 rue Leblanc, 75015, Paris, France, 2 GRADES, Université Paris-Sud, Université Paris-Saclay, 5 rue Jean-Baptiste Clément, 92290, Châtenay-Malabry, France, 3 Department of Health Economics, Gustave Roussy Institute, 114, rue Edouard-Vaillant, 94805, Villejuif, France

☯ These authors contributed equally to this work.
* nicolas.martelli@aphp.fr

Abstract

Context
Economic evaluations are far less frequently reported for medical devices than for drugs. In addition, little is known about the quality of existing economic evaluations, particularly for innovative devices, such as those used in vertebroplasty and kyphoplasty.

Objective
To assess the level of evidence provided by the available economic evaluations for vertebroplasty and kyphoplasty.

Data Sources
A systematic review of articles in English or French listed in the MEDLINE, PASCAL, COCHRANE and National Health Service Economic Evaluation databases, with limits on publication date (up to the date of the review, March 2014).

Study Selection
We included only economic evaluations of vertebroplasty or kyphoplasty. Editorial and methodological articles were excluded.

Data Extraction
Data were extracted from articles by two authors working independently and using two analysis grids to measure the quality of economic evaluations.
Data Synthesis

Twenty-one studies met our inclusion criteria. All were published between 2008 and 2014. Eighteen (86%) were full economic evaluations. Cost-effectiveness analysis (CEA) was the most frequent type of economic evaluation, and was present in 11 (52%) studies. Only three CEAs complied fully with the British Medical Journal checklist. The quality of the data sources used in the 21 studies was high, but the CEAs conforming to methodological guidelines did not use high-quality data sources for all components of the analysis.

Conclusions

This systematic review shows that the level of evidence in economic evaluations of vertebroplasty and kyphoplasty is low, despite the recent publication of a large number of studies. This finding highlights the challenges to be faced to improve the quality of economic evaluations of medical devices.

Introduction

Health technology assessment (HTA) is increasingly used to support healthcare allocation decisions in most health systems [1]. HTA ensures that decisions are based on the best evidence available. Indeed, health technologies are frequently seen as an important driver of rising health expenditure and one of the purposes of HTA is to analyze the economic implications of adopting new technologies [2]. Economic evaluations are thus an important source of information about health technologies. However, the methods currently used for economic evaluations of health products were initially developed with drugs in mind and are often unsuitable for medical devices [3]. Economic evaluations involve the collection of cost data, the establishment of clinical effectiveness and sensitivity analyses, but several of the specific features of medical devices may complicate such analyses [4]. First, devices evolve more rapidly than drugs. Consequently, new products are regularly released onto the market, with probable effects on prices and major effects on cost evaluation [5,6]. In addition, medical devices have wider economic implications that must be assessed, such as an impact on organization or a need for training. It is also challenging to design clinical trials for medical devices, and assessment methods must be modified for such trials [7]. It is often difficult to recruit large samples of patients, because most devices are suitable for use in only a limited number of patients. The procedures currently used to minimize study bias for drugs, such as blinding and randomization, are not always possible for surgical devices, for ethical or practical reasons [8]. Some devices are implantable and require very long-term follow-up that may be difficult to implement. Finally, device-operator interactions are very strong and can have a significant impact on the extent to which clinical results can be generalized. For all these reasons, large randomized controlled trials (RCTs) providing valid and unbiased estimates of efficacy are difficult to achieve for medical devices.

As a result, far fewer economic evaluations of medical devices than of drugs have been published [2,9]. In view of the constraints associated with medical devices, questions also remain about the level of evidence provided by the few economic evaluations available. It would also be useful to focus on surgical procedures in which innovative devices are used and for which economic evaluations through a HTA assessment process are clearly valuable. We identified vertebroplasty and kyphoplasty as particularly good case studies in this context. Both are procedures for treating the consequences of osteoporosis, a disease that is becoming increasing
frequent with the aging of the population in Western countries [10]. Indeed, osteoporosis is the
most common cause of vertebral compression fractures (VCFs), which have short-term effects,
such as acute and chronic pain, but are also associated with long-term morbidity [11]. The
management of VCFs is therefore a matter of public health concern. Vertebroplasty and
kyphoplasty are minimally invasive procedures, with broad economic implications, due to
their impact on the organization of healthcare institutions, the need to train medical teams and
the ability of these techniques to decrease the frequency of postoperative complications. They
do not treat the primary disease itself, but can improve the quality of life of patients. Finally,
the cost of the medical devices used for these procedures is higher than that of the standard
treatment for VCF pain (i.e. optimal pain management (OPM) with oral analgesics).

The aim of this systematic review was to assess the level of evidence provided by the avail-
able economic evaluations for vertebroplasty and kyphoplasty. In this work, we did not aim to
assess the cost-effectiveness or value of these procedures. Our aim was purely to illustrate the
level of published evidence available for economic evaluations of medical devices through a
particular example.

Materials and Methods

Study Selection

A systematic literature review was conducted to identify economic evaluations of vertebro-
plasty and kyphoplasty. Relevant studies were identified from the following databases: MED-
LINE, PASCAL, COCHRANE and the National Health Service Economic Evaluation Database
(NHS EED) at the University of York. Searches were undertaken in March 2014, with no limi-
tations concerning publication date. The search strategy was developed in MEDLINE and was
then adapted for the other databases. The search terms employed included: Cementoplasty/
economics[Mesh]; "Costs and Cost Analysis"[Mesh] AND "Cementoplasty"[Mesh]; "Econom-
ics"[Mesh] AND "Cementoplasty"[Mesh]; cost[Title/Abstract] AND kyphoplasty[Title/
Abstract]; cost[Title/Abstract]) AND vertebroplasty[Title/Abstract]. We are aware that
"cementoplasty" is a broad term encompassing vertebroplasty and kyphoplasty, but also other
procedures, such as osteoplasty and sacroplasty.

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines for this systematic review (S1 Checklist) [12]. The titles and abstracts
were first screened independently by CD and NM, to determine whether they met the inclusion
or exclusion criteria. We thus identified and excluded duplicate and irrelevant abstracts. We
then carried out a full-text review of all the texts retained at the end of the initial screening step.
Studies were included if they met the following criteria: (i) the study conducted was an eco-
nomic evaluation on vertebroplasty or kyphoplasty, (ii) the article concerned was written in
English or French. We excluded editorial or methodological studies and articles for which no
full-text format was available.

Data Collation and Analysis

We used two different methods to evaluate the level of evidence provided by the studies
included. This methodology was inspired by previous works on the quality of economic evalua-
tions in healthcare [13].

First, we considered the extent to which the study complied with methodological recom-
endations from internationally recognized guidelines published by Drummond et al. and
generally referred to as the British Medical Journal (BMJ) checklist [14,15]. These recommen-
dations provide general guidance about the way in which the results of economic evaluations
should be reported. The authors are required to indicate the study perspective (the point of
view from which the study is conducted), to provide a description of comparators, to specify
the type of costs used for the analysis, to report the incremental cost-effectiveness ratio (ICER),
to perform uncertainty analysis and to disclose funding sources. Using this method, two
researchers (CD and NM) extracted the following data independently from each of the studies
included: authors’ names, publication year, country of origin, type of economic evaluation, per-
spective, time window of the study, description of comparators, type of costs used, ICER calcu-
ation, uncertainty analysis and source of funding. The different types of economic evaluation
carried out were classified as follows: (i) partial economic evaluation (PEE), (ii) cost-minimiza-
tion analysis (CMA), (iii) cost-effectiveness analysis (CEA), (iv) cost-utility analysis (CUA) and
(v) cost-benefit analysis (CBA) [14]. The studies were considered to include a PEE if the compar-
ison did not include both the costs and consequences of therapeutic strategies [14]. By contrast,
CMA, CEA, CUA and CBA were considered to be full economic evaluations. In cases of discor-
dant classifications, the two researchers discussed discrepancies until a consensus was reached.

We then used the hierarchy scale developed by Cooper et al. [16] to assess the quality of evi-
dence from the data sources used in the studies included. With this scale, study quality is
gauged from the model used to obtain the data. The hierarchy scale is presented in S1 Table.
For example, the data used to assess patient outcomes (clinical effect and safety) are awarded a
score of one to six where “one” corresponds to the highest quality study design (meta-analysis
of RCTs with direct comparison between comparator therapies) and “six” is the lowest quality
study design (expert opinion). A score of nine is attributed if the data sources are not clearly
indicated. Scores were again attributed by two researchers (CD and NM) working indepen-
dently and discrepancies were discussed until a consensus was reached. Finally, we grouped the
ranks into three quality levels: A, B and C. Level A corresponds to the highest level of evidence
quality, covering ranks 1 and 2. Level B corresponds to an intermediate level of evidence qual-
ity, covering ranks 3 and 4. Ranks 5, 6 and 9 were grouped together in level C, corresponding
to the lowest level of evidence quality.

Results
Study Selection
In total, we identified 103 unique references. An initial review of titles and abstracts led to the
exclusion of 80 references, in which no economic evaluation was conducted. We therefore car-
ried out full-text reviews of 23 articles, two of which were excluded because they were published
in German (Fig 1). All 21 references retained were published between 2008 and 2014, with a
peak in the number of relevant articles published in 2013 (7/21, 33%).

Characteristics of the Studies Included
The characteristics of the 21 economic evaluations are summarized in Table 1 [17–37]. Eleven
of the 21 studies included (52%) contained CEAs, five (24%) contained CMAs, three (14%) con-
tained PEEs and two (10%) contained CUAs. Thus, 18 (86%) of the studies included con-
tained full economic evaluations.

Information about compliance with the BMJ checklist for the reporting of economic evalua-
tions is presented in Table 2. Two different perspectives were found in the studies included:
societal and hospital perspectives. The majority of the studies considered (57%) carried out
economic analyses from a societal perspective. Four of the 21 studies (19%) provided no com-
parators. Most studies (71%) used direct costs for the analysis. The time windows considered
ranged from 4 months to 11 years, and the median study duration was 35 months. The study
with the longest time window was classified as a CMA. Four CEAs and one CUA presented an
ICER calculation together with an uncertainty analysis. Only three CEAs carried out the
References identified through database searching

\[ n = 125 \]
- PubMed: \( n = 102 \)
- NHS EED: \( n = 12 \)
- Cochrane: \( n = 11 \)

Additional references identified through other sources

\[ n = 0 \]

References screened after removal of duplicates

\[ n = 103 \]

Titles and abstracts excluded

No economic evaluation

\[ n = 80 \]

Full text selected and reviewed

\[ n = 23 \]

Full text excluded

Articles in German

\[ n = 2 \]

References included in the review

\[ n = 21 \]
analysis from a societal perspective, used a comparator and considered total costs. One of these three studies concluded that kyphoplasty was cost-effective, relative to vertebroplasty, for the treatment of VCFs [19]. Another established that, for patients with an acute vertebral fracture due to osteoporosis, it was not possible to demonstrate the cost-effectiveness of kyphoplasty relative to standard medical treatment [21]. Finally, the third study concluded that kyphoplasty for the treatment of painful hospitalized vertebral fractures was cost-effective relative to non-

Table 1. Characteristics of the 21 economic evaluations reviewed.

| Reference          | Year | Country | Economic evaluation | Perspective | Cost included | Comparator | Uncertainty analysis | ICER | Sources of funding | Time window (months) |
|--------------------|------|---------|---------------------|-------------|---------------|------------|---------------------|------|-------------------|---------------------|
| Becker et al. [17] | 2011 | Austria | CEA                 | Hospital    | Direct        | Yes        | No                  | No   | Private           | 48                  |
| Chew et al. [18]   | 2013 | UK      | CUA                 | Societal    | Direct        | No         | No                  | No   | None              | 4                   |
| Edidin et al. [19] | 2012 | USA     | CEA                 | Societal    | Total         | Yes        | Yes                 | Yes  | Private           | 48                  |
| Flug et al. [20]   | 2013 | USA     | PEE                 | Hospital    | Total         | Yes        | No                  | N/A  | None              | 30                  |
| Fritzell et al. [21]| 2011 | Sweden  | CEA                 | Societal    | Total         | Yes        | Yes                 | Yes  | Private           | 35                  |
| Gan et al. [22]    | 2013 | China   | PEE                 | Hospital    | Direct        | Yes        | No                  | No   | Public            | 84                  |
| Goz et al. [23]    | 2013 | USA     | CEA                 | Societal    | Direct        | Yes        | No                  | No   | None              | 72                  |
| Gray et al. [24]   | 2008 | USA     | PEE                 | Societal    | Direct        | Yes        | No                  | No   | N/A               | 48                  |
| Hart et al. [25]   | 2008 | USA     | CMA                 | Hospital    | Direct        | Yes        | Yes                 | Yes  | N/A               | 25                  |
| Itagaki et al. [26]| 2012 | USA     | CEA                 | Societal    | Total         | Yes        | No                  | N/A  | None              | 120                 |
| Lad et al. [27]    | 2009 | USA     | CMA                 | Hospital    | Direct        | Yes        | No                  | No   | N/A               | 132                 |
| Lange et al. [28]  | 2014 | Germany | CEA                 | Societal    | Direct        | Yes        | No                  | N/A  | Private           | 60                  |
| Masala et al. [29] | 2008 | Italy   | CEA                 | Hospital    | Direct        | Yes        | No                  | Yes  | None              | 12                  |
| Mehio et al. [30]  | 2011 | USA     | CMA                 | Hospital    | Total         | Yes        | No                  | N/A  | Private           | 24                  |
| Ong et al. [31]    | 2013 | USA     | CMA                 | Societal    | Direct        | Yes        | No                  | N/A  | Private           | 60                  |
| Ström et al. [32]  | 2010 | Sweden  | CEA                 | Societal    | Total         | Yes        | Yes                 | Yes  | Private           | 12                  |
| Svedbom et al. [33]| 2012 | Sweden  | CEA                 | Societal    | Direct        | Yes        | Yes                 | Yes  | Private           | 24                  |
| Takura et al. [34] | 2013 | Japan   | CUA                 | Societal    | Direct        | No         | Yes                 | Yes  | None              | 12                  |
| Tang et al. [35]   | 2011 | China   | CEA                 | Hospital    | Direct        | Yes        | No                  | No   | None              | 46                  |
| Voidey et al. [36] | 2013 | France  | CMA                 | Societal    | Direct        | No         | No                  | N/A  | None              | 32                  |
| Zampini et al. [37]| 2010 | USA     | CEA                 | Hospital    | Direct        | Yes        | No                  | No   | None              | 12                  |

CEA: Cost-effectiveness analysis; CMA: Cost-minimization analysis; CUA: Cost-utility analysis; ICER: Incremental cost-effectiveness ratio; N/A: Not applicable; PEE: Partial economic evaluation

doi:10.1371/journal.pone.0144892.t001
surgical management [32]. However, it should be borne in mind that these conclusions are valid solely in the context in which these studies were carried out.

Eight of the 12 studies with a societal perspective (67%) used direct costs for the analysis. Funding sources were specified in all studies. There was no direct funding for 10 (48%) studies. Only three (14%) studies were funded by the public sector. The eight (38%) remaining studies were funded by profit-making organizations (medical device companies in all cases).

Quality of the Data Sources Used in the Economic Evaluations Reviewed

We used the hierarchy scale of Cooper et al. to classify the data sources used in the 21 studies included. The details of this analysis are shown in Table 3. The data sources for determining clinical effect sizes and safety were of the highest level of quality (A) for 12 studies (57%), whereas one study (5%) used data sources of poor quality (C). For the baseline clinical data, nine studies (43%) used poor-quality data (level C). Six of these nine studies did not indicate surgical management [32]. However, it should be borne in mind that these conclusions are valid solely in the context in which these studies were carried out.

Eight of the 12 studies with a societal perspective (67%) used direct costs for the analysis. Funding sources were specified in all studies. There was no direct funding for 10 (48%) studies. Only three (14%) studies were funded by the public sector. The eight (38%) remaining studies were funded by profit-making organizations (medical device companies in all cases).

Quality of the Data Sources Used in the Economic Evaluations Reviewed

We used the hierarchy scale of Cooper et al. to classify the data sources used in the 21 studies included. The details of this analysis are shown in Table 3. The data sources for determining clinical effect sizes and safety were of the highest level of quality (A) for 12 studies (57%), whereas one study (5%) used data sources of poor quality (C). For the baseline clinical data, nine studies (43%) used poor-quality data (level C). Six of these nine studies did not indicate surgical management [32]. However, it should be borne in mind that these conclusions are valid solely in the context in which these studies were carried out.

Eight of the 12 studies with a societal perspective (67%) used direct costs for the analysis. Funding sources were specified in all studies. There was no direct funding for 10 (48%) studies. Only three (14%) studies were funded by the public sector. The eight (38%) remaining studies were funded by profit-making organizations (medical device companies in all cases).

Quality of the Data Sources Used in the Economic Evaluations Reviewed

We used the hierarchy scale of Cooper et al. to classify the data sources used in the 21 studies included. The details of this analysis are shown in Table 3. The data sources for determining clinical effect sizes and safety were of the highest level of quality (A) for 12 studies (57%), whereas one study (5%) used data sources of poor quality (C). For the baseline clinical data, nine studies (43%) used poor-quality data (level C). Six of these nine studies did not indicate surgical management [32]. However, it should be borne in mind that these conclusions are valid solely in the context in which these studies were carried out.

Eight of the 12 studies with a societal perspective (67%) used direct costs for the analysis. Funding sources were specified in all studies. There was no direct funding for 10 (48%) studies. Only three (14%) studies were funded by the public sector. The eight (38%) remaining studies were funded by profit-making organizations (medical device companies in all cases).

Quality of the Data Sources Used in the Economic Evaluations Reviewed

We used the hierarchy scale of Cooper et al. to classify the data sources used in the 21 studies included. The details of this analysis are shown in Table 3. The data sources for determining clinical effect sizes and safety were of the highest level of quality (A) for 12 studies (57%), whereas one study (5%) used data sources of poor quality (C). For the baseline clinical data, nine studies (43%) used poor-quality data (level C). Six of these nine studies did not indicate surgical management [32]. However, it should be borne in mind that these conclusions are valid solely in the context in which these studies were carried out.

Eight of the 12 studies with a societal perspective (67%) used direct costs for the analysis. Funding sources were specified in all studies. There was no direct funding for 10 (48%) studies. Only three (14%) studies were funded by the public sector. The eight (38%) remaining studies were funded by profit-making organizations (medical device companies in all cases).
their sources. Only one (5%) study specifically analyzed administrative databases covering patients from the jurisdiction of interest. The data sources used to analyze resource use were of high quality for almost all studies, as 19 studies (91%) used level A information sources. The data sources for determining costs were also generally of high quality, with 15 studies (71%) using information sources of ranks 1 and 2. Nevertheless, the data used in two studies (10%) were extracted from level C data sources, and one of these two studies did not clearly state the sources of the information used.

By combining the two analyses, we focused on the quality of evidence used by the three CEAs in complete accordance with methodological recommendations. One study used sources from level A for each data component except for the determination of baseline clinical data, but this was not clearly stated in the paper. Another study used level A sources for all data components except clinical effect size and safety, for which the data were extracted from sources with a rank of 4 (level B). Finally, the data for the third study were extracted from level A sources for two components and from level B sources for three components.

Discussion

This systematic review identified 21 economic evaluations of vertebroplasty and kyphoplasty. We found that a wide variety of methods had been used for economic evaluations and their reporting, with major differences between studies in the type of economic evaluation, perspective used, costs, time horizons and quality of evidence used to perform the analysis.

Most of the studies did not fully comply with the BMJ checklist. One of the most common flaws observed was a lack of ICER calculation. ICER is particularly useful for decision-makers, because it simplifies the comparison of two mutually exclusive interventions and clearly indicates the additional benefits to be gained from an intervention [14]. If ICER is to be a valuable tool for decision-making support, it must be followed by a sensitivity analysis to assess the uncertainty on the calculation and to determine the robustness of the conclusions drawn. Again, very few of the CEAs included proposed a sensitivity analysis, and this rendered the results difficult to interpret. It is difficult to determine whether ICER and/or sensitivity analyses were not provided due to missing data or due to an inability of the authors to perform such analyses correctly. The rationale behind the decision not to perform such evaluations was only very rarely explained. Total costs were thus analyzed from a societal perspective in only a minority of studies. Such evaluations should, as far as possible, be carried out from a societal perspective when assessing the overall costs of the interventions. In the case of vertebroplasty and kyphoplasty, the use of a societal perspective is particularly relevant because productivity losses are a major component of the impact to be assessed [38]. The use of such a perspective would ensure that indirect costs associated with these interventions were not dismissed out of hand. Finally, all the studies included clearly specified the source of funding. This is a positive point, but it also raises ethical questions, because most of the studies complying with the BMJ checklist were funded directly by medical device companies. Several authors have already suggested that studies sponsored by industry are much more likely to reach favorable qualitative conclusions than similar studies funded by not-for-profit organizations [39–41]. There may be a number of reasons for this, such as the submission only of analyses with positive results or the selection of study strategies that industry is likely to fund. Unfortunately, the level of involvement of the sponsor in the study was not clearly indicated in any of the studies included. For example, it would have been useful to know whether the final version of the manuscript had to be approved by the sponsor before its submission [40].

The quality of the data sources used for the economic evaluations was generally high. However, this observation might conceal significant differences between data components. For
example, information on resource use was determined with high-quality data in almost all studies, whereas the sources of baseline clinical data were frequently of poor quality or not stated. One possible explanation for these discrepancies is that some data are undoubtedly harder to obtain than others, particularly for medical devices [42]. For example, it is difficult to account for all the cost items associated with medical device use, because these products often have far-reaching consequences for organization affecting many components [4]. Caution is also required concerning the implementation of the hierarchy scale applied here. Data from level A sources may well be of better quality than those from lower level sources. However, there is no guarantee that they were generated without bias. For example, two RCTs, FREE and VERTOS, were widely used in the 21 economic evaluations for the determination of clinical effect sizes and safety [43,44]. In a recent HTA report from the National Institute for Health Research, nine RCTs on percutaneous vertebroplasty and kyphoplasty, including FREE and VERTOS [45], were reviewed in depth. The authors identified several methodological issues and biases in both these studies, including a lack of blinding and attrition bias. We have already mentioned the many difficulties involved in RCTs on medical devices, including device-operator interactions, small sample sizes and the need for long-term follow-up [8]. Caution is therefore required when using RCTs on medical devices as data sources, because RCTs may not necessarily be based on unbiased data. We also found that even the CEAs complying fully with the BMJ checklist did not use high-quality sources of data for all the necessary components of the analysis. Thus, none of the studies reviewed here carried out a full economic evaluation reported complete information and used high-quality data for all analysis components. Other studies have identified methodological flaws in economic evaluations in healthcare, regardless of the type of intervention or health product [46–49]. It is, therefore, difficult to attribute these flaws exclusively to the type of health product studied here: medical devices. The methodological quality of economic evaluations is a global issue and the particular features of medical devices are not sufficient to account for the use of poor-quality sources revealed here.

Finally, this review has several limitations worthy of discussion. First, we restricted the selection of studies to those written in French and English. This led to the elimination of two studies written in German that were potentially relevant for our analysis. We used several databases, but some economic evaluation studies are probably published in data sources other than scientific journals. In this review, we focused exclusively on articles published in scientific journals and did not include economic evaluations from gray literature. Finally, assessment of the quality of economic evaluations is difficult and can be subjective. This point has already been highlighted by a number of authors [50,51].

**Conclusion**

Our findings show that the level of evidence used in economic evaluations of vertebroplasty/kyphoplasty is quite low despite the large number of studies published recently. We believe that this work is a good proxy, reflecting the quality of economic evaluations available for innovative medical devices. However, further studies on other medical devices are required to confirm these results. Finally, if efforts are not made to improve the quality of economic evaluations of medical devices and their reporting, then the resource allocation decisions based on these evaluations will remain uncertain.

**Supporting Information**

S1 Checklist. PRISMA statement.

(DOC)
S1 Dataset. BMJ checklist completed. (XLS)
S2 Dataset. Cooper checklist completed. (XLS)
S1 Table. Hierarchy scale for data sources in economic evaluations from Cooper et al. (DOCX)

Author Contributions
Conceived and designed the experiments: NM CD JP. Performed the experiments: NM CD. Analyzed the data: NM CD. Contributed reagents/materials/analysis tools: NM CD. Wrote the paper: NM CD HVDB PP JP IB.

References
1. Drummond MF, Schwartz JS, Jönsson B, Luce BR, Neumann PJ, Siebert U, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care. 2008; 24: 244–258. doi:10.1017/S0266462308080343 PMID: 18601792
2. Sorenson C, Drummond, Bhuiyan-Khan. Medical technology as a key driver of rising health expenditure: disentangling the relationship. ClinicoEconomics and Outcomes Research. 2013; 223. doi: 10.2147/CEOR.S39634
3. Drummond M, Griffin A, Tarricone R. Economic Evaluation for Devices and Drugs—Same or Different? Value Health. 2009; 12: 402–404. doi:10.1111/j.1524-4733.2008.00476_1.x PMID: 19138306
4. Kirisits A, Redekop WK. The economic evaluation of medical devices: challenges ahead. Appl Health Econ Health Policy. 2013; 11: 15–26. doi: 10.1007/s40258-012-0006-9 PMID: 23329383
5. Cookson R, Hutton J. Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective. Health Policy. 2003; 63: 167–178. PMID: 12543529
6. Iglesias CP. Does assessing the value for money of therapeutic medical devices require a flexible approach? Expert Review of Pharmacoeconomics & Outcomes Research. 2015; 15: 21–32. doi: 10.1586/14737167.2015.982098
7. Mohandas A, Foley K. Medical Devices: Adapting to the Comparative Effectiveness Landscape. BioTechnol Healthc. 2010; 7: 28–29. PMID: 22478818
8. Sedrakyan A, Marinac-Dabic D, Normand S-LT, Mushlin A, Gross T. A framework for evidence evaluation and methodological issues in implantable device studies. Med Care. 2010; 48: S121–128. doi: 10.1097/MLR.0b013e3181b991c4 PMID: 20421824
9. Boudard A, Martelli N, Prognon P, Pineau J. Clinical studies of innovative medical devices: what level of evidence for hospital-based health technology assessment? J Eval Clin Pract. 2013; 19: 697–702. doi: 10.1111/jep.12024 PMID: 23510375
10. Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism. 2008; 22: 671–685. doi: 10.1016/j.beem.2008.06.001
11. Silverman SL. The clinical consequences of vertebral compression fracture. Bone. 1992; 13: S27–S31. doi:10.1016/8756-3282(92)90193-Z PMID: 1627411
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery. 2010; 8: 336–341. doi: 10.1016/j.ijjsu.2010.02.007 PMID: 20171303
13. Teerawattananon DY, Russell S, Mugford M. A Systematic Review of Economic Evaluation Literature in Thailand. PharmacoEconomics. 2012; 25: 467–479. doi: 10.2165/00019053-200725060-00003
14. Torrance GW, Drummond MF. Methods for the economic evaluation of health care programmes. Oxford university press; 2005.
15. Shemilt I, Mugford M, Byford S, Drummond M, Eisenstein E, Knapp M, et al. Incorporating economics evidence. Cochrane handbook for systematic reviews of interventions. 2008; 449–480.
16. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997. Journal of health services research & policy. 2005; 10: 245–250.
17. Becker S, Pfeiffer KP, Ogon M. Comparison of inpatient treatment costs after balloon kyphoplasty and non-surgical treatment of vertebral body compression fractures. European Spine Journal. 2011; 20: 1259–1264. doi: 10.1007/s00586-011-1692-y PMID: 21290150

18. Chew C, O’Dwyer PJ, Edwards R. Health service cost associated with percutaneous vertebroplasty in patients with spinal metastases. Clinical radiology. 2013; 68: 776–779. doi: 10.1016/j.crad.2013.02.009 PMID: 23587476

19. Edidin AA, Ong KL, Lau E, Schmier J, Kemner JE, Kurtz SM. Cost-effectiveness analysis of treatments for vertebral compression fractures. Applied health economics and health policy. 2012; 10: 273–284. doi: 10.2165/11633220-00000000-00000 PMID: 22591065

20. Flug J, Hanford A, Ortiz O. Vertebral augmentation versus conservative therapy for emergently admitted vertebral compression deformities: an economic analysis. Pain physician. 2012; 16: 441–445.

21. Fritzell P, Ohlin A, Borgström F. Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up. Spine. 2011; 36: 2243–2251. doi: 10.1097/BRS.0b013e182322dd0f PMID: 21912321

22. Gan M, Zou J, Song D, Zhu X, Wang G, Yang H. Is balloon kyphoplasty better than percutaneous vertebroplasty for osteoporotic vertebral biconcave-shaped fractures? Acta Radiologica. 2014; 55: 985–991. doi: 10.1177/0284185113511603 PMID: 24280137

23. Goz V, Errico TJ, Weinreb JH, Koehler SM, Lafage V, et al. Vertebroplasty and kyphoplasty: national outcomes and trends in utilization from 2005 through 2010. The Spine Journal. 2013; Available: http://www.sciencedirect.com/science/article/pii/S1529943013007079.

24. Gray DT, Hollingworth W, Onwudiwe N, Jarvik JG. Costs and state-specific rates of thoracic and lumbar vertebral fracture, 2001–2005. Spine. 2008; 33: 1905–1912. doi: 10.1097/BRS.0b013e1817bb0a4 PMID: 18623537

25. Hart RA, Prendergast MA, Roberts WG, Nesbit GM, Barnwell SL. Proximal junctional acute collapse cranial to multi-level lumbar fusion: a cost analysis of prophylactic vertebral augmentation. The Spine Journal. 2008; 8: 875–881. doi: 10.1016/j.spinee.2008.01.015 PMID: 18375188

26. Itagaki MW, Talenfeld AD, Kwan SW, Brunner JW, Mortell KE, Brunner MC. Percutaneous vertebroplasty and kyphoplasty for pathologic vertebral fractures in the Medicare population: safer and less expensive than open surgery. Journal of Vascular and Interventional Radiology. 2012; 23: 1423–1429. doi: 10.1016/j.jvir.2012.08.010 PMID: 23101914

27. Lad SP, Patil CG, Lad EM, Hayden MG, Boakye M. National trends in vertebral augmentation procedures for the treatment of vertebral compression fractures. Surgical neurology. 2009; 71: 580–584. doi: 10.1016/j.surneu.2008.02.043 PMID: 18514288

28. Lange A, Kasperk C, Alvares L, Sauermann S, Braun S. Survival and cost comparison of kyphoplasty and percutaneous vertebroplasty using German claims data. Spine. 2014; 39: 318–326. doi: 10.1097/BRS.000000000000135 PMID: 24299715

29. Masala S, Ciarrapico AM, Konda D, Vinicola V, Mammucari M, Simonetti G. Cost-effectiveness of percutaneous vertebroplasty in osteoporotic vertebral fractures. European Spine Journal. 2008; 17: 1242–1250. doi: 10.1007/s00586-007-008-8 PMID: 18636280

30. Mehio AK, Lerner JH, Engelhart LM, Kozma CM, Slaton TL, Edwards NC, et al. Comparative hospital economics and patient presentation: vertebroplasty and kayplasty for the treatment of vertebral compression fracture. American Journal of Neuroradiology. 2011; 32: 1290–1294. doi: 10.3174/ajnr.A2502 PMID: 21546460

31. Ong KL, Lau E, Kemner JE, Kurtz SM. Two-year cost comparison of vertebroplasty and kyphoplasty for the treatment of vertebral compression fractures: are initial surgical costs misleading? Osteoporosis International. 2013; 24: 1437–1445. doi: 10.1007/s00198-012-2102-y PMID: 22890362

32. Ström O, Leonard C, Marsh D, Cooper C. Cost-effectiveness of balloon kyphoplasty in patients with symptomatic vertebral compression fractures in a UK setting. Osteoporosis international. 2010; 21: 1599–1608. doi: 10.1007/s00198-009-1096-6 PMID: 19924497

33. Svedbom A, Alvares L, Cooper C, Marsh D, Ström O. Balloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis. Osteoporosis International. 2013; 24: 365–367. doi: 10.1007/s00198-012-2102-y PMID: 22890362

34. Takura T, Yoshimatsu M, Sugimori H, Takizawa K, Furumatsu Y, Ikeda H, et al. Cost-Effectiveness Analysis of Percutaneous Vertebroplasty for Osteoporotic Compression Fractures. Journal of spine disorders & techniques. 2013; Available: http://europepmc.org/abstract/med/24141337.

35. Tang H, Zhao J, Hao C. Osteoporotic vertebral compression fractures: surgery versus non-operative management. Journal of International Medical Research. 2011; 39: 1438–1447. PMID: 21986146
36. Voidey A, Jehl-Rave M, Runge M, Godard J, Grumblat A, Limat S. Évaluation économique de la cyphoplastie. Le Pharmacien Hospitalier et Clinicien. 2014; 49: 77–82. doi: 10.1016/j.phclin.2013.05.008
37. Zampini JM, White AP, McGuire KJ. Comparison of 5766 vertebral compression fractures treated with or without kyphoplasty. Clinical Orthopaedics and Related Research 2010; 468:1773–80. doi: 10.1007/s11999-010-1279-7 PMID: 20177836
38. Zoański GH, Snow P, Olan WJ, Stallmeyer MB, Dick BW, Hebel JR, et al. Percutaneous vertebroplasty for osteoporotic compression fractures: quantitative prospective evaluation of long-term outcomes. Journal of Vascular and Interventional Radiology. 2002; 13: 139–148. PMID: 11830619
39. Azimi NA, Welch HG. The Effectiveness of Cost-Effectiveness Analysis in Containing Costs. J Gen Intern Med. 1998; 13: 664–669. doi: 10.1007/s11912-001-0027-2 PMID: 11489241
40. Barbieri M, Drummond MF. Conflict of interest in industry sponsored economic evaluations: Real or imagined? Curr Oncol Rep. 2001; 3: 410–413. doi: 10.1007/s11912-001-0027-2 PMID: 11489241
41. Liljas DB. How to Calculate Indirect Costs in Economic Evaluations. Pharmacoeconomics. 2012; 13: 1–7. doi: 10.2165/00019053-199813010-00001
42. Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009; 373: 1016–1024. doi: 10.1016/S0140-6736(09)60010-6 PMID: 19246088
43. Stevenson M, Gomersall T, Lloyd Jones M, Rawdin A, Hernández M, Dias S, et al. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014; 18: 1–290. doi: 10.3310/hta18170
44. Hoomans T, Severens JL, van der Roer N, Delwel GO. Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands. Pharmacoeconomics. 2012; 30: 219–227. doi: 10.2165/11539850-000000000-00000 PMID: 22074610
45. Jefferson T, Demicheli V, Vale L. Quality of systematic reviews of economic evaluations in health care. Jama. 2002; 287: 2809–2812. PMID: 12038919
46. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care. 2005; 43: 5–14. PMID: 16056003
47. Fotso Kamdem A, Nerich V, Auber F, Jantchou P, Ecarnot F, Woronoff-Lemsi M-C. Quality assessment of economic evaluation studies in pediatric surgery: a systematic review. J Pediatr Surg. 2015; 50: 659–687. doi: 10.1016/j.jpedsurg.2015.01.012 PMID: 25840083
48. Gerkens S, Crott R, Cleemput I, Thissen J-P, Closon M-C, Horsmans Y, et al. Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity. Int J Technol Assess Health Care. 2008; 24: 318–325. doi: 10.1017/S0266462308080422 PMID: 18601800
49. Walker DG, Wilson RF, Sharma R, Bridges J, Niessen L, Bass EB, et al. Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools. 2012; Available: http://www.ncbi.nlm.nih.gov/books/NBK114545. PMID: 23230577